Literature DB >> 25863013

Octreotide for malignant bowel obstruction: commentary on Currow et al.

Sebastiano Mercadante1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25863013     DOI： 10.1016/j.jpainsymman.2015.04.001

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN： 0885-3924            Impact factor:   3.612


× No keyword cloud information.
  4 in total

1.  Response to letter to the editor referencing-2016 updated MASCC/ESMO consensus recommendations: management of nausea and vomiting in advanced cancer.

Authors:  Carla I Ripamonti; Andrew Davies; Eduardo Bruera; Alex Molassiotis; Declan Walsh
Journal:  Support Care Cancer       Date:  2017-08-07       Impact factor: 3.603

Review 2.  Updates in palliative care - recent advancements in the pharmacological management of symptoms.

Authors:  Angela Star; Jason W Boland
Journal:  Clin Med (Lond)       Date:  2018-02       Impact factor: 2.659

3.  Development of a core outcome set to use in the research and assessment of malignant bowel obstruction: protocol for the RAMBO study.

Authors:  Elin Baddeley; Alison Bravington; Miriam Johnson; David C Currow; Fliss Em Murtagh; Elaine Boland; George Obita; Annmarie Nelson; Kathy Seddon; Alfred Oliver; Simon Noble; Jason Boland
Journal:  BMJ Open       Date:  2020-06-28       Impact factor: 2.692

4.  Symptom burden and lived experiences of patients, caregivers and healthcare professionals on the management of malignant bowel obstruction: A qualitative systematic review.

Authors:  Elin Baddeley; Mala Mann; Alison Bravington; Miriam J Johnson; David Currow; Fliss E M Murtagh; Elaine G Boland; George Obita; Alfred Oliver; Kathy Seddon; Annmarie Nelson; Jason W Boland; Simon I R Noble
Journal:  Palliat Med       Date:  2022-03-08       Impact factor: 5.713
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.